ArticleJournal of cellular and molecular medicine2026
MRPS16 Regulates NFATC2 Through the Wnt/β-Catenin Pathway to Promote Glioma Proliferation.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRPS16 Regulates NFATC2 Through the Wnt/β-Catenin Pathway to Promote Glioma Proliferation.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There have been reports that overexpression of mitochondrial ribosomal protein S16 (MRPS16) can greatly improve the growth of tumour cells, migration and invasion abilities in many ways. However, the role of MRPS16 in glioma cell proliferation, which is closely associated with tumour malignancy, remains unclear. The study applied a human gene expression array to investigate the expression levels of genes within glioma tissues in comparison with normal brain tissue. By RT-PCR, cell counting, flow cytometry, MTT assays, colony formation and injection of mice, we deeply explored the role of MRPS16 in glioma cell growth and the underlying mechanism. MRPS16 expression was significantly higher in glioma tissues compared with normal brain tissues. In the cultured glioma cells, glioma cell proliferation was inhibited, and cell cycle arrest and cell apoptosis were induced after MRPS16 knockdown. In BALB/c mice inoculated with glioma cells knocked down for MRPS16, it was found that tumour proliferation and growth were relatively slower than the control. Through further prediction and gene transformation of cultured cells, it is confirmed that the presence of MRPS16 promotes the proliferation of glioma cells through the Wnt/β-catenin/NFATC2 pathway. MRPS16 and NFATC2 promote glioma cell proliferation, which was confirmed by in vivo BALB/c mice inoculation. The Wnt/β-Catenin/NFATC2 pathway plays a role in promoting glioma cell proliferation by MRPS16, which is shown in our experimental data. Inhibition of MRPS16 may be a promising and effective treatment option for gliomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.